UNSPSC 51294505: Femoxetine

This classification denotes a serotonin agonist with the molecular formula C20H25NO2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 8Y719ZLX8C, chemically known as piperidine, 3-((4-methoxyphenoxy)methyl)-1-methyl-4-phenyl-, (3r-trans)- but generally known as femoxetine, which bears US NIH Compound Identifier 43103. European Medicines Agency schedules Femoxetine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07530MIG.

UNSPSC 51294505 Femoxetine is a Commodity code that does not align with the state and local procurement activity currently tagged to it. The three most recent opportunities posted under this code — a Seminole County, Florida naloxone and drug deactivation systems IFB, a Texas Health and Human Services Commission RFI on direct-to-manufacturer prescription programs, and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) RFP for generic multi-source pharmaceuticals and OTC products — are substantially unrelated to femoxetine specifically. The code shows little relevant recent activity; the opportunities reflect broader pharmaceutical procurement (naloxone overdose reversal agents, generic multi-source drugs, and pharmacy benefit program restructuring) rather than procurement of this specific antidepressant compound. Issuing bodies include county health departments, state HHS agencies, and regional cooperative purchasing alliances, but the scope mismatch suggests these tags may reflect cataloging error or broad pharmaceutical categorization rather than intentional procurement of femoxetine itself.

No state and local solicitations for femoxetine as a line item or primary commodity appear in the recent-opportunities block. The geographic spread captures Florida, Texas, and Minnesota activity, but this reflects the mis-tagged opportunities rather than a true signal of femoxetine demand. Business development professionals evaluating this code should verify whether state and local governments actually procure femoxetine in standalone form or whether the code's historical tagging reflects a data structure that does not match current purchasing patterns in pharmaceuticals at the state and local level.